Bleomycin-induced flagellate dermatitis

Flagellate pigmentation represents a unique adverse effect of bleomycin therapy that is encountered in 8–22% of patients. But this occurrence is independent of dose, route of administration, and underlying disorder (including type of malignancy). We highlight a case of a middle-aged man who developed flagellate hyperpigmentation following bleomycin-containing combined chemotherapy for Hodgkin’s lymphoma. Early recognition of bleomycin as the culprit drug is of paramount importance as these patients are usually on multiple medications.

Abstract licence: CC BY-NC-SA

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.